The DOI matches its Crossref record; 128 of the 129 references it cites were found in a registry or an index.
The blockade of immune checkpoints in cancer immunotherapy
Open accessAbstract
Among the most promising approaches to activating therapeutic antitumour immunity is the blockade of immune checkpoints. Immune checkpoints refer to a plethora of inhibitory pathways hardwired into the immune system that are crucial for maintaining self-tolerance and modulating the duration and amplitude of physiological immune responses in peripheral tissues in order to minimize collateral tissue damage. It is now clear that tumours co-opt certain immune-checkpoint pathways as a major mechanism of immune resistance, particularly against T cells that are specific for tumour antigens. Because many of the immune checkpoints are initiated by ligand-receptor interactions, they can be readily blocked by antibodies or modulated by recombinant forms of ligands or receptors. Cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) antibodies were the first of this class of immunotherapeutics to achieve US Food and Drug Administration (FDA) approval. Preliminary clinical findings with blockers of additional immune-checkpoint proteins, such as programmed cell death protein 1 (PD1), indicate broad and diverse opportunities to enhance antitumour immunity with the potential to produce durable clinical responses.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Recently, immunotherapies have shown promising results for reducing metastasis in melanoma or kidney cancer patients[1, 2].”
From Microfluidics: A New Tool for Modeling Cancer–Immune Interactions (2016) · cites this paper as [2]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Under normal physiological conditions, inhibitory immune checkpoint molecules are essential to maintain self-tolerance and prevent autoimmunity [1,2]”
From Characterizing the molecular regulation of inhibitory immune checkpoints with multimodal single-cell screens (2021) · cites this paper as [2]
In the citing paper
“there was strong down-regulation of several proteins with potential roles in modifying the response to immunotherapies exclusively in co-culture conditions, including CXCR4 (CD184), c-KIT (CD117) and KDR (CD309)23,24”
From Multimodal pooled Perturb-CITE-seq screens in patient models define mechanisms of cancer immune evasion (2021) · cites this paper as [23]
In the citing paper
“There is an active imbalance between stimulatory and inhibitory B7 family members in the tumor microenvironment [1,3,7,8].”
From T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment (2013) · cites this paper as [3]
In the citing paper
“Furthermore, TGF-β signaling in T cells activates SHP1 expression, which represses protein tyrosine kinase activities required for TCR signaling203,204.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [204]
In the citing paper
“In monotherapy, checkpoint inhibitors have resulted in impressive effects and durable responses in patients with highly refractory and late-stage cancers, such as metastatic melanoma and non-small cell lung cancer (NSCLC) [216].”
From Three decades of messenger RNA vaccine development (2019) · cites this paper as [216]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Foxp3 programs the development and function of CD4+CD25+ regulatory T cells
Fontenot, J. D., Gavin, M. A., & Rudensky, A. Y. (2003) · Nature Immunology · doi:10.1038/ni904 · Cited by 7,745
PD-1 and Its Ligands in Tolerance and Immunity
Keir, M. E., Butte, M. J., Freeman, G. J., & Sharpe, A. H. (2008) · Annual Review of Immunology · doi:10.1146/annurev.immunol.26.021607.090331 · Cited by 5,378
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
Dong, H., Strome, S. E., Salomao, D. R., Tamura, H., Hirano, F., Flies, D. B., Roche, P. C., Lu, J., Zhu, G., Tamada, K., et al. (2002) · Nature Medicine · doi:10.1038/nm730 · Cited by 5,025
Restoring function in exhausted CD8 T cells during chronic viral infection
Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J., & Ahmed, R. (2005) · Nature · doi:10.1038/nature04444 · Cited by 4,057
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Flagged first, then by citations
1 of the 129 references couldn’t be matched to a known paper.
Research works printed but not linked: 1
- Taube, J. M. et al. B7-H1 expression co-localizes with inflammatory infiltrates in benign and malignant melanocytic lesions: implications for immunotherapy. Sci. Transl. Med. (In the press, 2012). Introduction of the adaptive immune resistance hypothesis that proposes that the expression of immune-checkpoint ligand by tumours can be induced by an antitumour immune response as an adaptive immune-protective mechanism.
Cited by
Sorted by citations
Items 501–600 of 1,126
The prognostic landscape of tumor-infiltrating immune cell and immunomodulators in lung cancer
Liu, X., Wu, S., Yang, Y., Zhao, M., Zhu, G., & Hou, Z. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.08.003 · Cited by 347
Hu, Z., & Ma, D. (2018) · Cancer Medicine · doi:10.1002/cam4.1501 · Cited by 353
Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer
Nosho, K. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i2.557 · Cited by 344
The evolution of checkpoint blockade as a cancer therapy: what's here, what's next?
Shin, D. S., & Ribas, A. (2015) · Current Opinion in Immunology · doi:10.1016/j.coi.2015.01.006 · Cited by 351
Inflammation‐Triggered Cancer Immunotherapy by Programmed Delivery of CpG and Anti‐PD1 Antibody
Wang, C., Sun, W., Wright, G., Wang, A. Z., & Gu, Z. (2016) · Advanced Materials · doi:10.1002/adma.201506312 · Cited by 346
Treatment of Advanced Melanoma in 2020 and Beyond
Jenkins, R. W., & Fisher, D. E. (2020) · Journal of Investigative Dermatology · doi:10.1016/j.jid.2020.03.943 · Cited by 365
Three decades of messenger RNA vaccine development
Verbeke, R., Lentacker, I., De Smedt, S. C., & Dewitte, H. (2019) · Nano Today · doi:10.1016/j.nantod.2019.100766 · Cited by 342
Emerging roles of p53 and other tumour-suppressor genes in immune regulation
Muñoz‐Fontela, C., Mandinova, A., Aaronson, S. A., & Lee, S. W. (2016) · Nature reviews. Immunology · doi:10.1038/nri.2016.99 · Cited by 344
Li, J., Yu, X., Jiang, Y., He, S., Zhang, Y., Luo, Y., & Pu, K. (2020) · Advanced Materials · doi:10.1002/adma.202003458 · Cited by 342
Emerging Therapeutic Strategies to Overcome Drug Resistance in Cancer Cells
Garg, P., Malhotra, J., Kulkarni, P., Horne, D., Salgia, R., & Singhal, S. S. (2024) · Cancers · doi:10.3390/cancers16132478 · Cited by 339
Zheng, H., Zhao, W., Yan, C., Watson, C. C., Massengill, M. T., Xie, M., Massengill, C., Noyes, D. R., Martinez, G. V., Afzal, R., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2584 · Cited by 341
Suarez, E. R., Chang, D.-K., Sun, J., Sui, J., Freeman, G. J., Signoretti, S., Zhu, Q. K., & Marasco, W. A. (2016) · Oncotarget · doi:10.18632/oncotarget.9114 · Cited by 350
PD-1 and its ligands are important immune checkpoints in cancer
Dong, Y., Sun, Q., & Zhang, X. (2016) · Oncotarget · doi:10.18632/oncotarget.13895 · Cited by 350
High response rate to PD-1 blockade in desmoplastic melanomas
Eroglu, Z., Zaretsky, J. M., Hu-Lieskovan, S., Kim, D. W., Algazi, A., Johnson, D. B., Liniker, E., Kong, B., Munhoz, R., Rapisuwon, S., et al. (2018) · Nature · doi:10.1038/nature25187 · Cited by 338
Mansfield, A. S., Aubry, M., Moser, J. C., Harrington, S. M., Dronca, R. S., Park, S. S., & Dong, H. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw289 · Cited by 345
What does PD-L1 positive or negative mean?
Ribas, A., & Hu‐Lieskovan, S. (2016) · The Journal of Experimental Medicine · doi:10.1084/jem.20161462 · Cited by 348
Humanized mice in studying efficacy and mechanisms of PD‐1‐targeted cancer immunotherapy
Wang, M., Yao, L., Cheng, M., Cai, D., Martínek, J., Pan, C.-X., Shi, W., Ma, A., White, R. D., Airhart, S. D., et al. (2017) · The FASEB Journal · doi:10.1096/fj.201700740r · Cited by 345
From mice to humans: developments in cancer immunoediting
Teng, M. W. L., Galon, J., Fridman, W.-H., & Smyth, M. J. (2015) · Journal of Clinical Investigation · doi:10.1172/jci80004 · Cited by 337
TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM
Hung, A. L., Maxwell, R., Theodros, D., Belcaid, Z., Mathios, D., Luksik, A. S., Kim, E. S., Wu, A., Xia, Y., Garzón-Muvdi, T., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1466769 · Cited by 343
Self-citationTriple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies
Salcedo, J. M. M., Oza, G., Sharma, A. K., Arriaga, L., Hernández, J. M. H., Rotello, V. M., & Tapia-Ramı́rez, J. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17062078 · Cited by 348
Dewson, G., Eichhorn, P. J. A., & Komander, D. (2023) · Nature reviews. Cancer · doi:10.1038/s41568-023-00633-y · Cited by 353
Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer
Touat, M., Maisonobe, T., Knauß, S., Salem, O. B. H., Hervier, B., Auré, K., Szwebel, T., Kramkimel, N., Lethrosne, C., Bruch, J.-F., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000006124 · Cited by 341
Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma
Atefi, M. S., Avramis, E. V., Lassen, A., Wong, D. J. L., Robert, L., Foulad, D. S., Cerniglia, M., Titz, B., Chodon, T., Graeber, T. G., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2797 · Cited by 344
Plimack, E. R., Joaquim Bellmunt, B., Gupta, S., Berger, R., Chow, L. Q. M., Juco, J. W., Lunceford, J. K., Saraf, S., Perini, R. F., & O’Donnell, P. H. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30007-4 · Cited by 336
Biomimetic Nanotechnology toward Personalized Vaccines
Zhou, J., Kroll, A. V., Holay, M., Fang, R. H., & Zhang, L. (2019) · Advanced Materials · doi:10.1002/adma.201901255 · Cited by 336
Potential Impact of the Multi-Target Drug Approach in the Treatment of Some Complex Diseases
Makhoba, X. H., Viegas, C., Mosa, R. A., Viegas, F. P. D., & Pooe, O. J. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s257494 · Cited by 337
Wang, C., Wu, Z., Wang, Y., Guo, Y., Dai, H., Wang, X., Li, X., Zhang, Y.-J., Zhang, W., Chen, M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1365 · Cited by 335
A Review on Nano-Based Drug Delivery System for Cancer Chemoimmunotherapy
Mu, W., Chu, Q., Liu, Y., & Zhang, N. (2020) · Nano-Micro Letters · doi:10.1007/s40820-020-00482-6 · Cited by 336
Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors
Merchant, M. S., Wright, M., Baird, K., Wexler, L. H., Rodriguez-Galindo, C., Bernstein, D., Delbrook, C., Lodish, M., Bishop, R., Wolchok, J. D., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0491 · Cited by 331
Systematic Immunotherapy Target Discovery Using Genome-Scale In Vivo CRISPR Screens in CD8 T Cells
Dong, M. B., Wang, G., Chow, R. D., Ye, L., Zhu, L., Dai, X., Park, J. J., Kim, H. R., Errami, Y., Guzman, C. D., et al. (2019) · Cell · doi:10.1016/j.cell.2019.07.044 · Cited by 330
“Approved immune checkpoint inhibitors enhance anti-tumor response of CD8 T cells by neutralizing CTLA-4 or PD-1/PD-L1 (Brahmer et al., 2010; Kvistborg et al., 2014; Pardoll, 2012; Ribas, 2012; Swart et al., 2016; Tumeh et al., 2014).”
Breaking Down the Barriers to Precision Cancer Nanomedicine
von Roemeling, C., Jiang, W., Chan, C. K., Weissman, I. L., & Kim, B. Y. S. (2017) · Trends in Biotechnology · doi:10.1016/j.tibtech.2016.07.006 · Cited by 330
Pillai, R. N., Behera, M., Owonikoko, T. K., Kamphorst, A. O., Pakkala, S., Belani, C. P., Khuri, F. R., Ahmed, R., & Ramalingam, S. S. (2017) · Cancer · doi:10.1002/cncr.31043 · Cited by 337
Oncolytic viruses as therapeutic cancer vaccines
Bartlett, D. L., Liu, Z., Sathaiah, M., Ravindranathan, R., Guo, Z., He, Y., & Guo, Z. S. (2013) · Molecular Cancer · doi:10.1186/1476-4598-12-103 · Cited by 338
Ravi, R., Noonan, K. A., Pham, V., Bedi, R., Zhavoronkov, A., Ozerov, I. V., Makarev, E., V. Artemov, A., Wysocki, P. T., Mehra, R., et al. (2018) · Nature Communications · doi:10.1038/s41467-017-02696-6 · Cited by 325
Comprehensive Characterization of Molecular Differences in Cancer between Male and Female Patients
Yuan, Y., Liu, L., Chen, H., Wang, Y., Xu, Y., Mao, H., Li, J., Mills, G. B., Shu, Y., Li, L., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.001 · Cited by 325
Mimura, K., Teh, J. L., Okayama, H., Shiraishi, K., Kua, L., Koh, V., Smoot, D. T., Ashktorab, H., Oike, T., Suzuki, Y., et al. (2017) · Cancer Science · doi:10.1111/cas.13424 · Cited by 336
Hao, X., Zheng, Z., Liu, H., Zhang, Y., Kang, J., Kong, X., Rong, D., Sun, G., Sun, G., Liu, L., et al. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102463 · Cited by 325
Cheng, K., Ding, Y., Zhao, Y., Ye, S., Zhao, X., Zhang, Y., Ji, T., Wu, H., Wang, B., Anderson, G. J., et al. (2018) · Nano Letters · doi:10.1021/acs.nanolett.8b01071 · Cited by 325
Common risk factors for heart failure and cancer
Meijers, W. C., & de Boer, R. A. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz035 · Cited by 331
Kythreotou, A., Siddique, A., Mauri, F. A., Bower, M., & Pinato, D. J. (2017) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2017-204853 · Cited by 333
Liu, Y., Zugazagoitia, J., Ahmed, F. S., Henick, B. S., Gettinger, S. N., Herbst, R. S., Schalper, K. A., & Rimm, D. L. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1040 · Cited by 322
Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis
Waight, J. D., Netherby, C. S., Hensen, M. L., Miller, A., Hu, Q., Liu, S., Bogner, P. N., Farren, M. R., Lee, K. P., Liu, K., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68189 · Cited by 325
Herrera, A. F., Moskowitz, A. J., Bartlett, N. L., Vose, J. M., Ramchandren, R., Feldman, T. A., LaCasce, A. S., Ansell, S. M., Moskowitz, C. H., Fenton, K., et al. (2017) · Blood · doi:10.1182/blood-2017-10-811224 · Cited by 322
Combining Radiation and Immunotherapy: A New Systemic Therapy for Solid Tumors?
Tang, C. Z., Wang, X., Soh, H., Seyedin, S. N., Cortez, M. A., Krishnan, S., Massarelli, E., Hong, D. S., Naing, A., Diab, A. K., et al. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0069 · Cited by 325
Xiao, Y., Yu, S., Zhu, B., Bedoret, D., Bu, X., Francisco, L. M., Hua, P., Duke‐Cohan, J. S., Umetsu, D. T., Sharpe, A. H., et al. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20130790 · Cited by 330
Biomarker-guided therapy for colorectal cancer: strength in complexity
Sveen, A., Kopetz, S., & Lothe, R. A. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0241-1 · Cited by 320
POLE Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
van Gool, I. C., Eggink, F. A., Freeman-Mills, L., Stelloo, E., Marchi, E., de Bruyn, M., Palles, C., Nout, R. A., de Kroon, C. D., Osse, E. M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0057 · Cited by 323
Reporter gene imaging of targeted T cell immunotherapy in recurrent glioma
Keu, K. V., Witney, T. H., Yaghoubi, S. S., Rosenberg, J., Kurien, A., Magnusson, R., Williams, J. H. H., Habte, F. G., Wagner, J. R., Forman, S. J., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aag2196 · Cited by 322
Zhao, S., Ren, S., Jiang, T., Zhu, B., Li, X., Zhao, C., Jia, Y., Shi, J., Zhang, L., Liu, X., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0640 · Cited by 323
Anagnostou, V., Forde, P. M., White, J. R., Niknafs, N., Hruban, C., Naidoo, J., Marrone, K. A., Sivakumar, I. K. A., Bruhm, D. C., Rosner, S., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-1127 · Cited by 322
Self-citationDoi, T., Piha-Paul, S. A., Jalal, S. I., Saraf, S., Lunceford, J. K., Koshiji, M., & Bennouna, J. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.9846 · Cited by 318
Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity
Dorand, R. D., Nthale, J. M., Myers, J., Barkauskas, D. S., Avril, S., Chirieleison, S. M., Pareek, T. K., Abbott, D. W., Stearns, D. S., Letterio, J. J., et al. (2016) · Science · doi:10.1126/science.aae0477 · Cited by 324
Zhang, X., Zeng, Y., Qu, Q., Zhu, J., Liu, Z., Ning, W., Zeng, H., Zhang, N., Du, W., Chen, C., et al. (2017) · International Journal of Clinical Oncology · doi:10.1007/s10147-017-1161-7 · Cited by 316
Brody, R. S., Zhang, Y., Ballas, M. S., Siddiqui, M. K., Gupta, P., Barker, C., Midha, A., & Walker, J. (2017) · Lung Cancer · doi:10.1016/j.lungcan.2017.08.005 · Cited by 317
Immunogenic effects of chemotherapy-induced tumor cell death
Wang, Y., Fletcher, R., Yu, J., & Zhang, L. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.05.003 · Cited by 328
Beuselinck, B., Job, S., Becht, É., Karadimou, A., Verkarre, V., Couchy, G., Giraldo, N. A., Rioux-Leclercq, N. C., Molinié, V., Sibony, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1128 · Cited by 327
PD-1/PD-L1 and immunotherapy for pancreatic cancer
Feng, M., Xiong, G., Cao, Z., Yang, G., Zheng, S., Song, X., You, L., Zheng, L., Zhang, T., & Zhao, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.08.006 · Cited by 319
Neurological Complications Associated With Anti–Programmed Death 1 (PD-1) Antibodies
Kao, J. C., Liao, B., Markovic, S. N., Klein, C. J., Naddaf, E., Staff, N. P., Liewluck, T., Hammack, J. E., Sandroni, P., Finnes, H. D., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.1912 · Cited by 317
SHP2 inhibition prevents adaptive resistance to MEK inhibitors in multiple cancer models
Fedele, C., Ran, H., Diskin, B., Wei, W., Jen, J., Geer, M. J., Araki, K., Ozerdem, U., Simeone, D. M., Miller, G., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0444 · Cited by 315
Ritprajak, P., & Azuma, M. (2014) · Oral Oncology · doi:10.1016/j.oraloncology.2014.11.014 · Cited by 329
EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression
Peng, S., Wang, R., Zhang, X., Ma, Y., Zhong, L., Li, K., Nishiyama, A., Arai, S., Yano, S., & Wang, W. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1073-4 · Cited by 319
Song, W. L., Kuang, J., Li, C., Zhang, M., Zheng, D., Zeng, X., Liu, C., & Zhang, X. (2018) · ACS Nano · doi:10.1021/acsnano.7b09112 · Cited by 313
Wilgenhof, S., Corthals, J., Heirman, C., van Baren, N., Lucas, S., Kvistborg, P., Thielemans, K., & Neyns, B. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.4121 · Cited by 316
Time to abandon single-site irradiation for inducing abscopal effects
Brooks, E. D., & Chang, J. Y. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0119-7 · Cited by 315
Harnessing the immune system to improve cancer therapy
Papaioannou, N. E., Beniata, O. V., Vitsos, P., Tsitsilonis, O., & Samara, P. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.04.01 · Cited by 320
Combining Epigenetic and Immunotherapy to Combat Cancer
Chiappinelli, K. B., Zahnow, C. A., Ahuja, N., & Baylin, S. B. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-2125 · Cited by 313
CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients
Su, S., Hu, B., Shao, J., Shen, B., Du, J., Du, Y., Zhou, J., Yu, L., Zhang, L., Chen, F., et al. (2016) · Scientific Reports · doi:10.1038/srep20070 · Cited by 317
Bispecific Antibodies: From Research to Clinical Application
Ma, J., Mo, Y., Tang, M., Shen, J., Qi, Y., Zhao, W., Huang, Y., Xu, Y., & Qian, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.626616 · Cited by 321
Huang, R.-Y., Eppolito, C., Lele, S., Shrikant, P. A., Matsuzaki, J., & Odunsi, K. O. (2015) · Oncotarget · doi:10.18632/oncotarget.4751 · Cited by 316
Dynamic Changes in Chromatin Accessibility Occur in CD8 + T Cells Responding to Viral Infection
Scott-Browne, J. P., López-Moyado, I. F., Trifari, S., Wong, V., Chávez, L., Rao, A., & Pereira, R. M. (2016) · Immunity · doi:10.1016/j.immuni.2016.10.028 · Cited by 317
Pathology of triple negative breast cancer
Borri, F., & Granaglia, A. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.005 · Cited by 315
T cell–induced CSF1 promotes melanoma resistance to PD1 blockade
Neubert, N. J., Schmittnaegel, M., Bordry, N., Nassiri, S., Wald, N., Martignier, C., Tillé, L., Homicsko, K., Damsky, W., Maby-El Hajjami, H., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aan3311 · Cited by 308
Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non–Small Cell Lung Cancer
Dønnem, T., Hald, S. M., Paulsen, E., Richardsen, E. H., Al‐Saad, S., Kilvaer, T. K., Brustugun, O. T., Helland, Å., Lund‐Iversen, M., Poehl, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1905 · Cited by 316
Nirschl, C. J., & Drake, C. G. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-1972 · Cited by 322
NK cell-based immunotherapy for cancer.
Fang, F., Xiao, W.-H., & Tian, Z. (2017) · Seminars in Immunology · doi:10.1016/j.smim.2017.07.009 · Cited by 281
Siu, L. L., Even, C., Mesı́a, R., Remenár, É., Daste, A., Delord, J., Krauß, J., Saba, N. F., Nabell, L. M., Ready, N., et al. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2018.4628 · Cited by 312
Hogg, S. J., Vervoort, S. J., Deswal, S., Ott, C. J., Li, J., Cluse, L. A., Beavis, P. A., Darcy, P. K., Martin, B. P., Spencer, A., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.02.011 · Cited by 308
Shayan, G., Srivastava, R. M., Li, J., Schmitt, N. C., Kane, L., & Ferris, R. L. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1261779 · Cited by 312
Delivering safer immunotherapies for cancer
Milling, L. E., Zhang, Y., & Irvine, D. J. (2017) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2017.05.011 · Cited by 311
Immunotherapy for head and neck cancer: Recent advances and future directions
Cramer, J. D., Burtness, B. A., & Ferris, R. L. (2019) · Oral Oncology · doi:10.1016/j.oraloncology.2019.104460 · Cited by 316
Landscape of tumor-infiltrating T cell repertoire of human cancers
Li, B., Li, T., Pignon, J.-C., Wang, B., Wang, J., Shukla, S. A., Dou, R., Chen, Q., Hodi, F. S., Choueiri, T. K., et al. (2016) · Nature Genetics · doi:10.1038/ng.3581 · Cited by 306
Single-cell RNA-seq identifies a PD-1hi ILC progenitor and defines its development pathway
Yu, Y., Tsang, J. C. H., Wang, C., Clare, S., Wang, J., Chen, X., Brandt, C., Kane, L., Campos, L. S., Lu, L., et al. (2016) · Nature · doi:10.1038/nature20105 · Cited by 306
Antagonists of PD-1 and PD-L1 in Cancer Treatment
Lipson, E. J., Forde, P. M., Hammers, H.-J., Emens, L. A., Taube, J. M., & Topalian, S. L. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.05.013 · Cited by 309
Strength of PD-1 signaling differentially affects T-cell effector functions
Wei, F., Zhong, S., Ma, Z., Kong, H., Medvec, A. R., Ahmed, R., Freeman, G. J., Krogsgaard, M., & Riley, J. L. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1305394110 · Cited by 306
Immunotherapy and tumor microenvironment
Tang, H., Qiao, J., & Fu, Y. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.10.009 · Cited by 310
Concha‐Benavente, F., Srivastava, R. M., Trivedi, S., Lei, Y. L., Chandran, U. R., Seethala, R. R., Freeman, G. J., & Ferris, R. L. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-2001 · Cited by 313
A new dawn for eosinophils in the tumour microenvironment
Grisaru‐Tal, S., Itan, M., Klion, A. D., & Munitz, A. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0283-9 · Cited by 315
Chim, C. S., Kumar, S. K., Orlowski, R. Z., Cook, G., Richardson, P. G., Gertz, M. A., Giralt, S., Mateos, M. V., Leleu, X., & Anderson, K. C. (2018) · Leukemia · doi:10.1038/leu.2017.329 · Cited by 305
The role of tumor microenvironment in therapeutic resistance
Son, B., Lee, S., Youn, H., Kim, E., Kim, W., & Youn, B. (2016) · Oncotarget · doi:10.18632/oncotarget.13907 · Cited by 313
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors
Marabelle, A., Kohrt, H. E. K., Sagiv-Barfi, I., Ajami, B., Axtell, R. C., Zhou, G., Rajapaksa, R., Green, M. R., Torchia, J. A., Brody, J., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci73340 · Cited by 304
PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer
Yaghoubi, N., Soltani, A., Ghazvini, K., Hassanian, S. M., & Hashemy, S. I. (2018) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2018.11.105 · Cited by 307
Samanta, D., Park, Y., Ni, X., Li, H., Zahnow, C. A., Gabrielson, E., Pan, F., & Semenza, G. L. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1718197115 · Cited by 302
Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer
Choi, W., Czerniak, B. A., Ochoa, A. E., Su, X., Siefker-Radtke, A. O., Dinney, C. P., & McConkey, D. J. (2014) · Nature Reviews Urology · doi:10.1038/nrurol.2014.129 · Cited by 306
Li, S., Siriwon, N., Zhang, X., Yang, S., Jin, T., He, F., Kim, K. G., Mac, J., Lu, Z., Wang, S. P., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0867 · Cited by 309
Advanced hybrid nanomaterials for biomedical applications
Park, W., Shin, H., Choi, B., Rhim, W.-K., Na, K., & Han, D. K. (2020) · Progress in Materials Science · doi:10.1016/j.pmatsci.2020.100686 · Cited by 309
Anti–PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM
Mathios, D., Kim, J. E., Mangraviti, A., Phallen, J. A., Park, C., Jackson, C. M., Garzón-Muvdi, T., Kim, E. S., Theodros, D., Polanczyk, M. J., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aag2942 · Cited by 304
Self-citationRatcliffe, M., Sharpe, A. D., Midha, A., Barker, C., Scott, M. L. J., Scorer, P., Al‐Masri, H., Rebelatto, M. C., & Walker, J. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2375 · Cited by 303
Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape
Noguchi, T., Ward, J. P., Gubin, M. M., Arthur, C. D., Lee, S. H., Hundal, J., Selby, M. J., Graziano, R. F., Mardis, E. R., Korman, A. J., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0391 · Cited by 306
Precision diagnosis and treatment of liver cancer in China
Fu, J., & Wang, H. (2017) · Cancer Letters · doi:10.1016/j.canlet.2017.10.008 · Cited by 302
Dong, W., Wu, X., Ma, S., Wang, Y., Nalin, A. P., Zhu, Z. G., Zhang, J., Benson, D. M., He, K., Caligiuri, M. A., et al. (2019) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-1259 · Cited by 303
Metadata
- Authors
- Pardoll, D. M.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Pardoll, Drew M.
- ORCID
- Pardoll, Drew M.
- Venue
- Nature Reviews Cancer
- Published
- 2012-03-22
- Volume
- 12
- Issue
- 4
- Pages
- 252-264
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC4856023
- OpenAlex
- W2066671159
- Cited by
- 13,838
- References
- 129
- Citations by year
- 2026: 652 · 2025: 910 · 2024: 1153 · 2023: 1202 · 2022: 1302 · 2021: 1456 · 2020: 1409 · 2019: 1236 · 2018: 1197 · 2017: 1146 · 2016: 897 · 2015: 647 · 2014: 339 · 2013: 240 · 2012: 39
- FWCI
- 41.84
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Melanoma Research Alliance
- Hussman Foundation
- National Cancer Institute (P30CA021765, P30CA006973)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- immune checkpoint, cancer immunotherapy, immune checkpoint blockade, CTLA-4, PD-1, tumor immune evasion, antitumor immunity, self-tolerance, ligand-receptor interactions, antibody therapy, combination therapy, immune resistance
- MeSH terms
- Animals, Antigens, Neoplasm, Clinical Trials as Topic, Humans, Immunotherapy, Neoplasms, Tumor Escape, Cancer Vaccines, Molecular Targeted Therapy, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
